Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

432.10INR
3:55am GMT
Change (% chg)

Rs-1.35 (-0.31%)
Prev Close
Rs433.45
Open
Rs433.45
Day's High
Rs434.40
Day's Low
Rs430.20
Volume
762,905
Avg. Vol
10,596,986
52-wk High
Rs679.30
52-wk Low
Rs390.60

Latest Key Developments (Source: Significant Developments)

India Market Regulator Chief Tyagi Says Examining Complaint Made Against Sun Pharma By Whistleblower - ET NOW
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - :INDIA MARKET REGULATOR CHIEF TYAGI SAYS STARTED ADJUDICATION PROCESS AGAINST 3 RATING COS IN IL&FS CASE - ET NOW.INDIA MARKET REGULATOR CHIEF TYAGI SAYS IN TALKS WITH CENBANK ON COMMERCIAL PAPER MARKET TRANSPARENCY - ET NOW.INDIA MARKET REGULATOR CHIEF TYAGI SAYS BOARD APPROVES CHANGES TO OFFER-FOR-SALE MECHANISM RULES - ET NOW.INDIA MARKET REGULATOR CHIEF TYAGI SAYS EXAMINING COMPLAINT MADE AGAINST SUN PHARMA <<>> BY WHISTLEBLOWER - ET NOW.  Full Article

Sun Pharmaceutical Industries Gets FDA Approval For Generic Ganirelix Acetate Injection
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS US FDA APPROVAL FOR GENERIC GANIRELIX ACETATE INJECTION.SUN PHARMACEUTICAL INDUSTRIES - COMMERCIALIZATION OF GENERIC GANIRELIX ACETATE INJECTION IN U.S. MARKET IS EXPECTED IN Q4FY19..  Full Article

Sun Pharmaceutical Industries Says Unit To Buy Pola Pharma Inc, Japan For 100 Mln Japanese Yen
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Sun Pharmaceutical Industries Ltd ::UNIT TO BUY POLA PHARMA INC., JAPAN, FOR A CASH CONSIDERATION OF 100 MILLION JAPANESE YEN.  Full Article

India's Sun Pharmaceutical Industries Posts Sept-Qtr Loss
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Sun Pharmaceutical Industries Ltd ::SEPT QUARTER CONSOL NET LOSS 2.19 BILLION RUPEES VERSUS PROFIT OF 9.12 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL PROFIT WAS 10.35 BILLION RUPEES.SEPT QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 69.38 BILLION RUPEES VERSUS 66.50 BILLION RUPEES LAST YEAR.SAYS SEPT QUARTER EXCEPTIONAL ITEM OF 12.14 BILLION RUPEES.  Full Article

India's Sun Pharma Sees Low Double-Digit Topline Growth In FY 2018-19 Consol Revenues
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Sun Pharmaceutical Industries Ltd ::SEES A LOW DOUBLE-DIGIT TOPLINE GROWTH IN CO'S CONSOLIDATED REVENUES FOR FISCAL 2018-19 OVER LAST YEAR.SUN PHARMACEUTICAL INDUSTRIES - EXPECT NORMALIZATION OF THE INDIA BUSINESS IN THE CURRENT YEAR POST THE DISRUPTION LAST YEAR DUE TO GST IMPLEMENTATION.SUN PHARMACEUTICAL INDUSTRIES - EXPECTING REASONABLE GROWTH IN EMERGING MARKETS BUSINESS, HOWEVER, CURRENCY FLUCTUATIONS CONTINUE TO BE A RISK.SHORT-TERM OUTLOOK FOR U.S. GENERICS MARKET CONTINUES TO BE CHALLENGING GIVEN THE PRICING PRESSURES.  Full Article

Sun Pharma Industries Gets Australian Regulator Approval For Psoriasis Drug
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Sun Pharmaceutical Industries Ltd ::RECEIVED AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL FOR SPECIALITY PRODUCT, ILUMYA.SUN PHARMACEUTICAL INDUSTRIES- DRUG FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY.  Full Article

Sun Pharma Announces U.S. FDA Approval Of Cequa To Treat Dry Eye Disease
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SUN PHARMA ANNOUNCES U.S. FDA APPROVAL OF CEQUA™ TO TREAT DRY EYE DISEASE.  Full Article

Sun Pharmaceutical Industries Says Sales In U.S. Were $380 Mln In Q1, Up 8 Pct
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS SALES IN THE U.S WERE US$ 380 MILLION FOR THE QUARTER, A GROWTH OF 8% OVER SAME PERIOD LAST YEAR.SUN PHARMACEUTICAL INDUSTRIES - CREATING PIPELINE OF SPECIALTY PRODUCTS; DURING THE YEAR LAUNCHES WILL RESULT IN SIGNIFICANT UPFRONT INVESTMENTS.  Full Article

India's Sun Pharmaceutical Industries Posts June Qtr Consol Profit
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::JUNE QUARTER CONSOL NET PROFIT 9.83 BILLION RUPEES VERSUS LOSS OF 4.25 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL PROFIT WAS 8.97 BILLION RUPEES.JUNE QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 72.24 BILLION RUPEES VERSUS 62.09 BILLION RUPEES LAST YEAR.  Full Article

Sun Pharmaceutical Industries Launches Novel Drug Kapspargo Sprinkle In USA
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO LAUNCHES NOVEL DRUG KAPSPARGO SPRINKLE IN USA.  Full Article

Indian shares rise as banks rally, inflation eases sharply

Dec 13 Indian shares climbed to a more than one-week high on Thursday after inflation eased sharply in November, and the new central bank governor's move to open up a dialogue with lenders pushed up banking counters.